Ilypsa, Inc. Raises $36 Million For Kidney Drugs
10/19/2005 5:11:57 PM
July 20, 2005 -- Ilypsa Inc. has raised $36 million in a series B round, which the company said would provide enough cash for the next two years of operations. By that time, the company hopes to have completed Phase II tests of its two treatments for advanced renal disease. The company develops non-absorbed polymers which, sitting in the gut, absorb excess potassium, phosphate, and other electrolytes or metabolites that would normally be cleared by the kidney. We look at the drug candidates from the company and its history...
comments powered by